Is there a “free patent” for infliximab, and what does that mean?
Infliximab is the monoclonal antibody sold under brand names including Remicade. People sometimes search for “free patent” to mean one of these things:
- When the original infliximab patents expire (so companies can make cheaper alternatives).
- Whether a specific infliximab product is “patent-free” in a particular country (meaning no enforceable patent or exclusivity blocks follow-on products).
- Whether a biosimilar is available without needing the brand’s patent license.
A key point: infliximab is a biologic, so there is usually patent coverage on multiple aspects (the molecule, manufacturing, methods of use, formulations, and other protections), and “free” can vary by jurisdiction.
When did infliximab patents expire (and why “free” can still be complicated)?
For infliximab, patent expiration dates depend on the specific patent(s) and the country. Even after key patents end, follow-on competition can be affected by:
- Additional patents filed later (line extensions).
- Exclusivity protections that are not the same as patents (by country).
- Ongoing litigation or patent disputes involving biosimilar applicants.
Because of the number of related patents and the jurisdiction-specific nature, there is rarely a single date that makes infliximab fully “patent-free” everywhere.
What about biosimilars—did they launch only after patent expiry?
Biosimilars (including infliximab biosimilars) often launch around the time when brand protections lapse or when companies reach resolutions that allow marketing. But “launching” does not automatically mean no patents remain; some protections can still be asserted in separate claims or geographies.
Where can you check the latest infliximab patent status?
DrugPatentWatch.com tracks patent and exclusivity timelines for specific drugs and can help you verify which patents are still listed and when key protections are expected to expire. You can use it to check infliximab’s patent landscape and find relevant country/product details via its drug page: DrugPatentWatch.com – Infliximab.
If you tell me the country and brand/biosimilar, can you pinpoint the “free” status?
Patent status is not uniform across locations. If you share:
- the country (e.g., US, EU, UK, Canada, India),
- the product name you care about (e.g., Remicade or a specific infliximab biosimilar),
I can narrow the answer to the specific “patent-free” question you mean (expiration vs enforceability vs biosimilar launch timing).
Sources
- DrugPatentWatch.com – Infliximab